Safety and Preliminary Activity of BI115 in Advanced SCLC
Recruiting now · Phase 1
Conditions studied: Small Cell Lung Cancer (SCLC)
In brief
This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer
Key facts
- Study ID
- NCT07559019
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
- People needed
- 150
- Starts
- 2026-05-21
- Expected to finish
- 2030-03-30
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- the second affiliated hospital of AMU — Chongqing, Chongqing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.